Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-01-29 Sale | 2024-01-31 4:23 pm | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 1,250 | $65.22 | $81,524 | 57,208 (Direct) | View |
| 2024-01-23 Sale | 2024-01-24 4:03 pm | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 7,378 | $63.69 | $469,905 | 58,458 (Direct) | View |
| 2024-01-22 Sale | 2024-01-23 6:05 pm | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 1,607 | $65 | $104,449 | 65,836 (Direct) | View |
| 2024-01-17 Sale | 2024-01-18 4:55 pm | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 5,207 | $65.58 | $341,475 | 67,443 (Direct) | View |
| 2024-01-16 Sale | 2024-01-17 12:24 pm | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 438 | $66.81 | $29,262 | 101,017 (Direct) | View |
| 2023-12-26 Sale | 2023-12-28 4:13 pm | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 303 | $59.7 | $18,089 | 53,580 (Direct) | View |
| 2023-02-23 Sale | 2023-02-27 4:34 pm | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 1,646 | $68.76 | $113,179 | 53,883 (Direct) | View |
| 2023-01-30 Sale | 2023-01-31 4:51 pm | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 883 | $52.76 | $46,587 | 46,468 (Direct) | View |
| 2023-01-23 Sale | 2023-01-25 4:14 pm | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 4,479 | $51.58 | $231,027 | 47,718 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-01-16 Option Award | 2024-01-17 12:24 pm | N/A 2034-01-15 | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 28,367 | $66.3 | 101,017 (Direct) | View |
| 2024-01-16 Option Award | 2024-01-17 12:24 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 19,508 | $0 | 101,017 (Direct) | View |
| 2023-02-21 Tax Withholding | 2023-02-22 06:46 am | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 825 | $58.5 | 69,552 (Direct) | View |
| 2023-02-21 Option Award | 2023-02-22 06:46 am | N/A 2032-01-20 | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 23,909 | $0 | 69,552 (Direct) | View |
| 2023-01-27 Tax Withholding | 2023-01-30 4:58 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 367 | $52.77 | 47,351 (Direct) | View |
| 2023-01-20 Tax Withholding | 2023-01-24 5:15 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 2,033 | $52.05 | 52,197 (Direct) | View |
| 2023-01-12 Option Award | 2023-01-17 7:35 pm | N/A 2033-01-11 | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 35,472 | $52.66 | 89,702 (Direct) | View |
| 2023-01-12 Option Award | 2023-01-17 7:35 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer | 22,580 | $0 | 89,702 (Direct) | View |
| 2022-12-22 Tax Withholding | 2022-12-23 4:15 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Exec VP, Program Team Lead | 89 | $51.68 | 32,900 (Direct) | View |
| 2022-04-25 Other | 2022-12-23 4:15 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Exec VP, Program Team Lead | 1,250 | $0 | 32,900 (Direct) | View |
| 2022-01-28 Tax Withholding | 2022-02-01 6:09 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Exec VP, Program Team Lead | 434 | $38.59 | 32,989 (Direct) | View |
| 2022-01-21 Option Award | 2022-01-25 4:50 pm | N/A 2032-01-20 | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Exec VP, Program Team Lead | 63,002 | $0 | 70,374 (Direct) | View |
| 2021-12-22 Tax Withholding | 2021-12-23 4:49 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Exec VP, Program Team Lead | 89 | $47.82 | 7,372 (Direct) | View |
| 2021-03-01 Option Award | 2021-03-03 4:07 pm | N/A 2031-02-28 | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Exec VP, Program Team Lead | 8,750 | $0 | 14,961 (Direct) | View |
| 2021-01-28 Option Award | 2021-02-01 4:36 pm | N/A 2031-01-27 | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Exec VP, Program Team Lead | 35,000 | $0 | 36,211 (Direct) | View |
| 2020-12-23 Option Award | 2020-12-23 5:41 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Exec VP, Program Team Lead | 1,211 | $0 | 1,211 (Direct) | View |
Ownership | 2020-10-06 4:37 pm | N/A 2030-08-31 | Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey See Remarks | 0 | $0 | 125,000 (Direct) | View |